Current paradigm of HER2-low expression has been proposed, indicating low expression of the HER2 undetectable by standard methods, but still being a positive predictive factor. This novel in vivo approach allows the examination with optic fiber probe directly in the patient’s body without tissue extraction. The trial emphasized the safety of inPROBE®, reporting no significant device-related complications.